Advertisement

Central Nervous System Inflammation and Cholesterol Metabolism Alterations in the Pathogenesis of Alzheimer’s Disease and Their Diagnostic and Therapeutic Implications

  • Leonel E. Rojo
  • Jorge Fernández
  • José Jiménez
  • Andrea A. Maccioni
  • Alejandra Sekler
  • Rodrigo O. Kuljis
  • Ricardo B. Maccioni
Chapter

Abstract

During the last few years, an increasing amount of evidence points to the major role of deregulation of the interaction patterns between glial cells and neurons in the pathway toward neuronal degeneration. Central nervous system inflammation is a process associated with several neurodegenerative disorders, including Alzheimer’s disease (AD). Many hypotheses have been postulated to explain the pathogenesis of AD. Recent findings point to amyloid-β (Aβ) oligomers as responsible for synaptic impairment in neuronal degeneration, but amyloid abnormalities are among major factors affecting the function and survival of neuronal cells. The tau protein hypothesis has been developed and refined based on the fact that tau hyperphosphorylation and self-aggregation constitutes a common feature of most of the altered signaling pathways in AD. Known mediators of inflammation have been found in plaques, such as interleukin-1β, interleukin-6, and tumor necrosis factor-α. Additional evidence for the involvement of inflammation in AD is provided by epidemiological data and retrospective clinical data showing positive effects of nonsteroidal anti-inflammatory drugs. Cytokines and trophic factors produced by glial cells can trigger anomalous hyperphosphorylation of tau. Glial production of these mediators indicates that innate immunity is involved in AD. Thus, a neuroimmunological approach to AD becomes relevant. In this context, endogenous danger signals such as altered lipoproteins and oxidized lipids appear to affect glial cells, inducing release of such mediators. Indeed, when alterations of cholesterol metabolism occur, the neurochemical events of oxidative stress, Aβ peptide, and tau protein seem to represent a set of physiological mechanisms to respond to impaired brain cholesterol dynamics. All these mechanisms, for example, changes in neuroimmunomodulation, dislipidemias, cholesterol abnormalities, and other metabolic alterations, appear to be interrelated. To date, there are no specific diagnostic tools for AD that allow early treatment, thus improving quality of life for AD patients and reducing the morbidity and mortality associated with the late complications. Therefore, a search for innovative molecular markers for early diagnosis of AD is essential. Here we discuss the molecular aspects of the role of neuroinflammation and cholesterol in AD and some perspectives toward molecular early diagnosis.

Keywords

Cholesterol Metabolism Demented Patient Central Nervous System Inflammation Brain Cholesterol Nonamnestic Mild Cognitive Impairment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

Research was supported by the International Center for Biomedicine (ICC), FONDECYT grant 1080264, and by a grant from Arturo Prat University to LR.

References

  1. 1.
    Fernandez J, Rojo LE, Kuljis RO, Maccioni RB (2008) The damage signal hypothesis of Alzheimer’s disease pathogenesis. J Alzheimers Dis 14(3):329–333Google Scholar
  2. 2.
    Rojo LE, Fernández JA, Maccioni AA, Jimenez JM, Maccioni RB (2008) Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer’s disease. Arch Med Res 39:1–16PubMedCrossRefGoogle Scholar
  3. 3.
    Deservi B, La Porta CA, Bontempelli M, Comolli R (2002) Decrease of TGF-b1 plasma levels and increase of nitric oxide synthase activity in leukocytes as potential biomarkers of Alzheimer’s disease. Exp Gerontol 37:813–821CrossRefGoogle Scholar
  4. 4.
    Locatelli S, Lutjohann D, Schmidt HH-J, Otto C, Beisiegel U, von Bergmann K (2002) Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain. Arch Neurol 59:213–216PubMedCrossRefGoogle Scholar
  5. 5.
    Rojo L, Sjöberg MK, Hernández P, Zambrano C, Maccioni RB (2006) Roles of cholesterol and lipids in the etiopathogenesis of Alzheimer’s disease. J Biomed Biotechnol 2006:73976PubMedCrossRefGoogle Scholar
  6. 6.
    Reid PC, Urano Y, Kodama T, Hamakubo T (2007) Alzheimer’s disease: cholesterol, membrane rafts, isoprenoids and statins. J Cell Mol Med 11:383–392PubMedCrossRefGoogle Scholar
  7. 7.
    Lio JK, Laufs U (2005) Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45:89–118CrossRefGoogle Scholar
  8. 8.
    Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol 57:1439–1443PubMedCrossRefGoogle Scholar
  9. 9.
    Lio D, Annoni G, Licastro F, (2006) Tumor necrosis factorα-308A/G polymorphism is associated with age at onset of Alzheimer’s disease. Mech Ageing Dev 127:567–571PubMedCrossRefGoogle Scholar
  10. 10.
    Quintanilla RA, Orellana DI, González-Billault C, Maccioni RB (2004) Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. Exp Cell Res 295:245–257PubMedCrossRefGoogle Scholar
  11. 11.
    Orellana DI, Quintanilla RA, Gonzalez-Billault C, Maccioni RB (2005) Role of the JAKs/STATs pathway in the intracellular calcium changes induced by interleukin-6 in hippocampal neurons. Neurotox Res 8:295–304PubMedCrossRefGoogle Scholar
  12. 12.
    McGeer PL, Rogers J, McGeer EG (2006) Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. J Alzheimers Dis 9 (3 Suppl):271–276PubMedGoogle Scholar
  13. 13.
    Zambrano CA, Egaña JT, Núñez MT, Maccioni RB, González-Billault C (2004) Oxidative stress promotes tau dephosphorylation in neuronal cells: the roles of cdk5 and PP1. Free Radic Biol Med 36:1393–1402PubMedCrossRefGoogle Scholar
  14. 14.
    Bocci V (1998) Central nervous system toxicity of interferons and other cytokines. J Biol Regul Homeost Agents 2:107–118Google Scholar
  15. 15.
    Licinio J, Wong ML (1997) Pathways and mechanisms for cytokine signaling of the central nervous system. J Clin Invest 100:2941–2947PubMedCrossRefGoogle Scholar
  16. 16.
    Teunissen CE, de Vente J, Steinbusch HW, De Bruijn C (2002) Biochemical markers related to Alzheimer’s dementia in serum and cerebrospinal fluid. Neurobiol Aging 23:485–508PubMedCrossRefGoogle Scholar
  17. 17.
    Banks WA, Kastin AJ (1997) Relative contributions of peripheral and central sources to levels of IL-1a in the cerebral cortex of mice: assessment with species-specific enzyme immunoassays. J Neuroimmunol 79:22–28PubMedCrossRefGoogle Scholar
  18. 18.
    Galasko D (2005) Biomarkers for Alzheimer’s disease clinical needs and application. J Alzheimers Dis 8:339–346PubMedGoogle Scholar
  19. 19.
    Mocali A, Cedrola S, Della Malva N, (2004) Increased plasma levels of soluble CD40, together with the decrease of TGF beta 1, as possible differential markers of Alzheimer disease. Exp Gerontol 39:1555–1561PubMedCrossRefGoogle Scholar
  20. 20.
    Weaver JD, Huang MH, Albert M, Harris T, Rowe JW, Seeman TE (2002) Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging. Neurology 59:371–378PubMedGoogle Scholar
  21. 21.
    Sciacca FL, Ferri C, Licastro F, (2003) Interleukin-1B polymorphism is associated with age at onset of Alzheimer’s disease. Neurobiol Aging 24:927–931PubMedCrossRefGoogle Scholar
  22. 22.
    Griffin W (2008) Perispinal etanercept: potential as an Alzheimer therapeutic. J Neuroinflammation 5:3–5PubMedCrossRefGoogle Scholar
  23. 23.
    Comijs HC, Dik MG, Aartsen MJ, Deeg DJ, Jonker C (2005) The impact of change in cognitive functioning and cognitive decline on disability, well-being, and the use of healthcare services in older persons. Results of Longitudinal Aging Study Amsterdam. Dement Geriatr Cogn Disord 19:5–6Google Scholar
  24. 24.
    Maccioni RB, Lavados M, Maccioni CB, Farias G, Fuentes P (2006) Anomalously phosphorylated tau protein and Abeta fragments in the CSF of Alzheimer’s and MCI subjects. Neurobiol Aging 27:237–244PubMedCrossRefGoogle Scholar
  25. 25.
    Harding D, Brull D, Humphries SE, Whitelaw A, Montgomery H, Marlow N (2005) Variation in the interleukin-6 gene is associated with impaired cognitive development in children born prematurely: a preliminary study. Pediatr Res 58:117–120PubMedCrossRefGoogle Scholar
  26. 26.
    Braida D, Sacerdote P, Panerai AE, (2004) Cognitive function in young and adult IL (interleukin)-6 deficient mice. Behav Brain Res 153:423–429PubMedCrossRefGoogle Scholar
  27. 27.
    Murphy GM Jr, Claassen JD, DeVoss JJ, (2001) Rate of cognitive decline in AD is accelerated by the interleukin-1 alpha−889 *1 allele. Neurology 56:1595–1599PubMedGoogle Scholar
  28. 28.
    Pollmacher T, Haack M, Schuld A, Reichenberg A, Yirmiya R (2002) Low levels of circulating inflammatory cytokines, do they affect human brain functions? Brain Behav Immun 16:525–532PubMedCrossRefGoogle Scholar
  29. 29.
    Dimopoulos N, Piperi C, Salonicioti A, (2007) Characterization of the lipid profile in dementia and depression in the elderly. J Geriatr Psychiatry Neurol 20:138–144PubMedCrossRefGoogle Scholar
  30. 30.
    Yaffe K (2007) Metabolic syndrome and cognitive decline. Curr Alzheimer Res 4:123–126PubMedCrossRefGoogle Scholar
  31. 31.
    Sekler MA, Jiménez JM, Rojo LE, et al. (2008) Cognitive impairment associated with Alzheimer’s disease: links with cholesterol metabolism and oxidative stress. Neuropsychiatr Dis Treat 4: 4(4):715–722Google Scholar
  32. 32.
    Kivipelto M, Helkala EL, Laakso MP, (2001) Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ 322:1447–1451PubMedCrossRefGoogle Scholar
  33. 33.
    Sparks DL, Sabbagh MN, Breitner JC, Hunsaker JC 3rd; AD Cholestrol-Lowering Treatment Trial Team and the Ancillary ADAPT: Cholestrol and Statin Parameters Work Group; Cache County and ADAPT Work Groups; Eastern Division of the Kentucky Medical Examiner’s Group (2003) Is cholesterol a culprit in Alzheimer’s disease? Int Psychogeriatr 15 Suppl 1:153–159Google Scholar
  34. 34.
    Selley ML, Close DR, Stern SE (2002) The effect of increased concentrations of homocysteine on the concentration of (E)-4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer’s disease. Neurobiol Aging 23:383–388PubMedCrossRefGoogle Scholar
  35. 35.
    Bourdel-Marchasson I, Delmas-Beauvieux M-C, Peuchant E, (2001) Antioxidant defences and oxidative stress markers in erythrocytes and plasma from normally nourished elderly Alzheimer patients. Age Ageing 30:235–241PubMedCrossRefGoogle Scholar
  36. 36.
    Reitz C, Tang MX, Manly J, Schupf N, Mayeux R, Luchsinger JA (2008) Plasma lipid levels in the elderly are not associated with the risk of mild cognitive impairment. Dement Geriatr Cogn Disord 25:232–237PubMedCrossRefGoogle Scholar
  37. 37.
    Lutjohann D, Papassotiropoulos A, Bjorkhem I, (2000) Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J Lipid Res 41:195–198PubMedGoogle Scholar
  38. 38.
    Han X, Fagan AM, Cheng H, Morris JC, Xiong C, Holtzman DM (2003) Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia. Ann Neurol 54:115–119PubMedCrossRefGoogle Scholar
  39. 39.
    Komulainen P, Lakka TA, Kivipelto M, (2006) Metabolic syndrome and cognitive function: a population-based follow-up study in elderly women. Dement Geriatr Cogn Disord 23:29–34PubMedCrossRefGoogle Scholar
  40. 40.
    Blum-Degen D, Muller T, Kuhn W, Gerlach M, Przuntek H, Riederer P (1995) IL-1 beta, and IL-6 are elevated in the cerebrospinal fluid of Alzheimer’s, and de novo Parkinson’s disease patients. Neurosci Lett 202:17–20PubMedCrossRefGoogle Scholar
  41. 41.
    Martinez M, Fernandez-Vivancos E, Frank A, De la Fuente M, Hernanz A (2000) Increased cerebrospinal fluid fas (Apo-1) levels in Alzheimer’s disease. Relationship with IL-6 concentrations. Brain Res 869:216–219Google Scholar
  42. 42.
    Martinez M, Frank A, Hernanz A (1993) Relationship of interleukin-1 beta and beta 2-microglobulin with neuropeptides in cerebrospinal fluid of patients with dementia of the Alzheimer type. J Neuroimmunol 48:235–240PubMedCrossRefGoogle Scholar
  43. 43.
    Tarkowski E, Blennow K, Wallin A, Tarkowski A (1999) Intracerebral production of TNF-alpha, a local neuroprotective agent in Alzheimer disease and vascular dementia. J Clin Immunol 19:223–230PubMedCrossRefGoogle Scholar
  44. 44.
    Lanzrein AS, Johnston CM, Perry VH, Jobst KA, King EM, Smith AD (1998) Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: IL-1beta, IL-6, IL-1 receptor antagonist, TNF-alpha, the soluble TNF receptors I and II, and alpha1 – antichymotrypsin. Alzheimer Dis Assoc Disord 12:215–227PubMedCrossRefGoogle Scholar
  45. 45.
    Cacabelos R, Franco-Maside A, Alvarez XA (1991) Interleukin-1 in Alzheimer’s disease and multi-infarct dementia: neuropsychological correlations. Methods Find Exp Clin Pharmacol 13:703–708PubMedGoogle Scholar
  46. 46.
    Singh VK, Guthikonda P (1997) Circulating cytokines in Alzheimer’s disease. J Psychiatr Res 31:657–660PubMedCrossRefGoogle Scholar
  47. 47.
    Jia JP, Meng R, Sun YX, Sun WJ, Ji XM, Jia LF (2005) Cerebrospinal fluid tau, Abeta1–42 and inflammatory cytokines in patients with Alzheimer’s disease and vascular dementia. Neurosci Lett 383:12–16PubMedCrossRefGoogle Scholar
  48. 48.
    Alvarez A, Cacabelos R, Sanpedro C, García-Fantini M, Aleixandre M (2007) Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease. Neurobiol Aging 28:533–536PubMedCrossRefGoogle Scholar
  49. 49.
    Cacabelos R, Alvarez XA, Franco-Maside A, Fernandez-Novoa L, Caamano J (1994) Serum TNF in Alzheimer’s disease, and multi-infarct dementia. Methods Find Exp Clin Pharmacol 16:29–35PubMedGoogle Scholar
  50. 50.
    Shalit F, Sredni B, Stern L, Kott E, Huberman M (1994) Elevated interleukin-6 secretion levels by mononuclear cells of Alzheimer’s patients. Neurosci Lett 174:130–132PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Leonel E. Rojo
    • 1
  • Jorge Fernández
    • 1
  • José Jiménez
    • 1
  • Andrea A. Maccioni
    • 1
  • Alejandra Sekler
    • 1
  • Rodrigo O. Kuljis
    • 1
  • Ricardo B. Maccioni
    • 1
  1. 1.Laboratory of Cell and Molecular NeuroscienceDCPSc of Arturo Prat University and Mind/Brain Program of the ICCÑuñoaChile

Personalised recommendations